. Author manuscript; available in PMC: 2009 Nov 25.

Published in final edited form as: J Med Virol. 2009 Jan;81(1):65–74. doi: 10.1002/jmv.21360

Table 2.

IgG Subclass Distribution of anti-AAV2 Capsid Antibodies Following Intramuscular Administration of AAV2-hFIX Vector

Subject 01-01 (dose 2×10¹¹ vg/kg)
Time Point	IgG1¹	IgG2¹	IgG3¹	IgG4¹	IgM¹	Neutralizing Titer²,³

Baseline	28213	954	0	235	579	1:100
Week 3	30137	1051	0	293	666	1:5000
Week 7	26056	1100	0	310	1083	ND
Week 10	29558	1161	0	441	918	ND
Week 12	29639	1075	0	437	1073	1:1000
Subject 01–06 (dose 6×10¹¹ vg/kg)
Time Point	IgG1¹	IgG2¹	IgG3¹	IgG4¹	IgM¹	Neutralizing Titer²,³

Baseline	920	0	46	0	222	1
Day 2	8803	0	1120	0	581	ND
Week 1	11753	461	1444	60	956	ND
Week 2	9952	403	1449	58	298	ND
Week 4	9665	453	3719	58	505	1:1000
Week 8	24850	651	8141	59	619	ND
Subject 02–05 (dose 6×10¹¹ vg/kg)
Time Point	IgG1¹	IgG2¹	IgG3¹	IgG4¹	IgM¹	Neutralizing Titer²,³

Baseline	20103	596	0	373	316	1:100
Day 3	18418	825	0	458	333	ND
Week 1	22996	1778	294	1123	774	ND
Week 4	21377	2344	4442	1256	736	1:1000
Week 8	27396	2065	3329	606	517	ND
Week 12	23813	1375	4828	594	546	1:1000
Subject 02–07 (dose 2×10¹² vg/kg)
Time Point	IgG1¹	IgG2¹	IgG3¹	IgG4¹	IgM¹	Neutralizing Titer²,³

Baseline	18205	678	0	378	312	1:100
Day 1	19621	518	0	304	302	ND
Week 1	19763	1497	0	709	2244	ND
Week 2	23021	2270	0	782	1238	ND
Week 3	23975	1973	0	779	1411	1:10000
Week 12	20108	2298	1130	0	762	1:10000

Values shown represent antibody concentrations in ng/mL.

Neutralizing titer represents the highest dilution at which greater than or equal to 50% transduction occurs compared to controls. ND is not determined.

These data were previously published [Manno et al., 2003] and are added here for comparison.